

Intermittent Dosing of Dorsal Root Ganglion Stimulation as an Alternate Paradigm to Continuous Low-Frequency Therapy

NCT04909138

Status	RECRUITING
Phase	Not Applicable
Sponsor	Rush University Medical Center
Enrollment	30 participants

Key Eligibility Criteria

Inclusion (9)

- Age between 18 and 99
- year or more use of continuous DRG therapy as delivered a permanently implanted Abbott PROCLAIM XR Dorsal Root Ganglion Neurostimulator System for chronic back and/or leg pain
- Endorse at least 50% pain relief in the targeted area over the last year
- Must have been seen for routine follow-up within last 4 months
- Must have been reprogrammed in standard fashion at least once prior to randomization
- ... and 4 more (see full listing online)

Exclusion (5)

- Significant lead migration, as determined by clinician
- Other concurrent neuromodulation system in place
- Corticosteroid injection in previous 30 days prior to enrollment
- Intermittent dosing and/or failure within last 6m
- Changing or unstable pain medications within 30 days

Locations (1 total)

Rush University Medical Center, Chicago, Illinois, United States